Here we have reported a novel strategy to increase the efficiency of peptide-based cancer vaccines, using a dual approach of targeting the vaccine construct to XCR1+ cDC1 and enhancing antigen entry into the cross-presentation pathway through the use of an endosomal escape CPP. Here, XCR1 is linked to cancer.